ARCHIVES

Tafinlar Subgroup Data Shows Median OS of 20 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Patient Advocacy: Policy Should Prevent Employers From Using Genetic Test Results

April 11, 1997

Two-Drug Combination Extends Survival Of Mesothelioma

May 31, 2002

HHS Task Force Says NCI Drug Program Effective, Otters Suggestions; DeVita Responds

March 26, 1982

Gene Vector Labs Seek Vector Producers

February 23, 1996

Senate Subcommittee Adds $98 Million to NCI’s FY 1984 Budget, Assuring Substantial Increase

September 30, 1983

Advisors approve set-aside for alternative medicine “best case series.”

November 19, 2004